Showing 1 - 4 results of 4 for search 'Allan Tindikahwa', query time: 0.02s Refine Results
  1. 1
    How much does it cost to improve access to voluntary medical male circumcision among high-risk, low-income communities in Uganda?

    How much does it cost to improve access to voluntary medical male circumcision among high-risk, low-income communities in Uganda? by Bruce Larson, Allan Tindikahwa, George Mwidu, Hannah Kibuuka, Fred Magala

    Published 2015-01-01
    Get full text
    Article
  2. 2
    In-vitro Immunomodulatory activity of Azadirachta indica A.Juss. Ethanol: water mixture against HIV associated chronic CD4+ T-cell activation/ exhaustion

    In-vitro Immunomodulatory activity of Azadirachta indica A.Juss. Ethanol: water mixture against HIV associated chronic CD4+ T-cell activation/ exhaustion by Omalla A. Olwenyi, Bannet Asingura, Prossy Naluyima, Godwin Upoki Anywar, Justine Nalunga, Mariam Nakabuye, Michael Semwogerere, Bernard Bagaya, Fatim Cham, Allan Tindikahwa, Francis Kiweewa, Eliezer Z. Lichter, Anthony T. Podany, Courtney V. Fletcher, Siddappa N. Byrareddy, Hannah Kibuuka

    Published 2021-04-01
    Get full text
    Article
  3. 3
    HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.

    HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. by Francis Kiweewa, Allahna Esber, Ezra Musingye, Domonique Reed, Trevor A Crowell, Fatim Cham, Michael Semwogerere, Rosemary Namagembe, Alice Nambuya, Cate Kafeero, Allan Tindikahwa, Leigh Anne Eller, Monica Millard, Huub C Gelderblom, Babajide Keshinro, Yakubu Adamu, Jonah Maswai, John Owuoth, Valentine Chepkorir Sing'oei, Lucas Maganga, Emmanuel Bahemana, Samoel Khamadi, Merlin L Robb, Julie A Ake, Christina S Polyak, Hannah Kibuuka

    Published 2019-01-01
    Get full text
    Article
  4. 4
    Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

    Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials by Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team

    Published 2024-03-01
    Get full text
    Article

Search Tools: